CLARITAS PHARMACEUTICALS
Kalytera is pioneering the development of a next generation of cannabinoid therapeutics. Kalytera is focused first on developing a new class of proprietary cannabidiol (“CBD”) therapeutics.
CLARITAS PHARMACEUTICALS
Industry:
Biotechnology Cannabis Health Care Medical
Founded:
2004-10-15
Address:
San Rafael, California, United States
Country:
United States
Website Url:
http://www.claritaspharma.com
Total Employee:
11+
Status:
Active
Contact:
+1 888 861 2008
Email Addresses:
[email protected]
Total Funding:
27.18 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS GoDaddy DNS AWS Global Accelerator
Similar Organizations
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-02-16 | Talent Biotechs | Talent Biotechs acquired by Claritas Pharmaceuticals | N/A |
Investors List
Alumina Partners
Alumina Partners investment in Private Equity Round - Claritas Pharmaceuticals
Obsidian Global Partners
Obsidian Global Partners investment in Post-IPO Debt - Claritas Pharmaceuticals
Official Site Inspections
http://www.claritaspharma.com
- Host name: kenmorrison.clientshostname.com
- IP address: 104.193.255.153
- Location: Santa Clara United States
- Latitude: 37.3526
- Longitude: -121.9541
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95050
More informations about "Claritas Pharmaceuticals"
Claritas Pharmaceuticals - Crunchbase Company Profile …
Organization. Claritas Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ...See details»
Claritas Pharmaceuticals, Inc. (CLAZF) - Yahoo Finance Canada
See the company profile for Claritas Pharmaceuticals, Inc. (CLAZF) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Claritas Pharmaceuticals - Products, Competitors, Financials, …
Jul 19, 2023 claritaspharma.com. Overview & Products; About Claritas Pharmaceuticals. ... According to World Health Organization (2023), the prevalence of hypertension shows …See details»
Claritas Pharmaceuticals Inc - Company Profile and News
Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing therapies for patients with significant unmet …See details»
Kalytera Therapeutics Inc. Completes Name Change to Claritas ...
Apr 2, 2021 Company to Hold Annual and Special Meeting on June 17, 2021SAN FRANCISCO, April 02, 2021 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE …See details»
Claritas (formerly Kalytera Therapeutics, Inc.) to Collaborate with ...
Mar 3, 2021 The Phase 1 clinical study of intramuscular R-107 will be conducted at CMAX, a clinical contract research organization located at Royal Adelaide Hospital in Australia.See details»
Kalytera Therapeutics Inc. Completes Name Change to Claritas ...
SAN FRANCISCO, April 02, 2021 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the 'Company' or 'Kaly...See details»
Kalytera Therapeutics Inc. Completes Name Change to Claritas ...
SAN FRANCISCO, April 02, 2021 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today …See details»
Kalytera Therapeutics Inc. Completes Name Change to Claritas
Apr 2, 2021 --Kalytera Therapeutics, Inc. today announced that the Company has changed its name to Claritas Pharmaceuticals, Inc.. The new ticker symbol will be CLAS, pending final …See details»
Claritas Announces Approval from OTC to Up-List to OTCQB
Apr 7, 2022 SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the …See details»
Claritas Pharmaceuticals Issues Letter to Shareholders
May 11, 2021 www.claritaspharma.com. About Claritas Pharmaceuticals Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing …See details»
Claritas (formerly Kalytera Therapeutics, Inc.) to - GlobeNewswire
Mar 3, 2021 SAN FRANCISCO and TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and...See details»
FAQ - Claritas Pharmaceuticals
Claritas has exclusive rights under all patents to commercialize R-107 for treatment of COVID-19 infection. Claritas was granted these rights under an exclusive, world-wide license agreement …See details»
Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus …
Mar 1, 2021 SAN FRANCISCO and TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.), (TSX VENTURE …See details»
Claritas Completes Acquisition of Exclusive Worldwide
Dec 21, 2021 [email protected] 1 Pulmonary Arterial Hypertension Market Size Worth $9.8 Billion By 2027, Grand View Research, February 2020 2 Nitric Oxide and Pulmonary …See details»
Claritas Announces Approval from OTC to Up-List to OTCQB
Apr 7, 2022 SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the …See details»
Claritas Completes Acquisition of Exclusive Worldwide Rights to …
Dec 21, 2021 Data in Animal Model of PAH Demonstrate Ability of R-107 to Reverse Progression of the DiseaseSAN FRANCISCO, CA and TORONTO, ON, Dec. 21, 2021 …See details»
Claritas Pharmaceuticals, Inc. (CLAZF) - Yahoo Finance
Find the latest Claritas Pharmaceuticals, Inc. (CLAZF) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Claritas Provides Update Regarding Phase 1 Clinical Study
Nov 18, 2021 SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (theSee details»
Claritas Announces Option to Acquire Rights to Novel Drug for …
Sep 16, 2021 Highlights. The worldwide market for treatment of ARDS is projected to reach $934.8 million by 2026. 1 ARDS is one of the common clinical manifestations of severe COVID …See details»